Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

ConclusionsUpdated analyses demonstrate the long-term efficacy and safety of cabozantinib in Japanese patients with advanced RCC after at least one VEGFR-TKI therapy. Responders tended to show lower baseline HGF levels ClinicalTrials.gov Identifier: NCT03339219.

http://link.springer.com/10.1007/s10147-022-02283-w

Source: International Journal of Clinical Oncology - January 3, 2023 Category: Cancer & Oncology Source Type: research